Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects

Saved in:
Bibliographic Details
Published inPR Newswire
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 13.07.2021
Subjects
Brain cancer
Cardiotoxicity
Clinical trials
Drug dosages
FDA approval
Leukemia
Lungs
Metastasis
Pharmaceutical industry
Toxicity
Tumors
United States > US
HOUSTON
Online AccessGet full text

Cover

More Information
Description not available.